{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:00:15Z","timestamp":1791518415419,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05140-z","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:42:16Z","timestamp":1772077336000},"page":"12753-12757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RAS blockade in chronic kidney disease: Current evidence and future directions"],"prefix":"10.1007","volume":"399","author":[{"given":"Antonio","family":"Vitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Ponzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Boccellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"5140_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes. N Engl J Med 383:2219\u20132229","journal-title":"N Engl J Med"},{"key":"5140_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor\u2013associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685\u2013693","journal-title":"Arch Intern Med"},{"issue":"12","key":"5140_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861\u2013869","journal-title":"N Engl J Med"},{"key":"5140_CR4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ et al (2020) Effects of SGLT2 inhibition on renal hemodynamics and albuminuria. Circulation 142:1028\u20131039","journal-title":"Circulation"},{"issue":"14","key":"5140_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DCCT Research Group","year":"1993","unstructured":"DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977\u2013986","journal-title":"N Engl J Med"},{"issue":"13","key":"5140_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296\u20131305","journal-title":"N Engl J Med"},{"key":"5140_CR7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE et al (2018) Renoprotective effects of sodium\u2013glucose cotransporter-2 inhibitors. Lancet Diabetes Endocrinol 6:691\u2013704","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5140_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"},{"key":"5140_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117\u2013127","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"5140_CR10","first-page":"81","volume":"123","author":"NR Hill","year":"2013","unstructured":"Hill NR et al (2013) Epidemiology of chronic kidney disease and its cardiovascular implications. Nephron Clin Pract 123(1\u20132):81\u201390","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"5140_CR11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.ajkd.2009.03.018","volume":"54","author":"CY Hsu","year":"2009","unstructured":"Hsu CY et al (2009) Long-term effects of angiotensin-converting enzyme inhibitors in patients with chronic kidney disease. Am J Kidney Dis 54(4):693\u2013701","journal-title":"Am J Kidney Dis"},{"key":"5140_CR12","doi-asserted-by":"crossref","unstructured":"KDIGO (2024) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(Suppl 4):S1\u2013S150","DOI":"10.1016\/j.kint.2023.09.002"},{"issue":"9811","key":"5140_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","volume":"379","author":"AS Levey","year":"2012","unstructured":"Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165\u2013180","journal-title":"Lancet"},{"key":"5140_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Ohkuma T, Neal B et al (2019) Cardiovascular and renal outcomes with SGLT2 inhibitors across patient populations. Lancet 393:31\u201339","journal-title":"Lancet"},{"issue":"12","key":"5140_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH et al (2001) Losartan in patients with diabetic nephropathy. N Engl J Med 345(12):861\u2013869","journal-title":"N Engl J Med"},{"key":"5140_CR16","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"issue":"2","key":"5140_CR17","first-page":"137","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P et al (2004) Irbesartan in patients with diabetic nephropathy. N Engl J Med 351(2):137\u2013146","journal-title":"N Engl J Med"},{"issue":"2","key":"5140_CR18","first-page":"c68","volume":"113","author":"DA Sica","year":"2009","unstructured":"Sica DA et al (2009) Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of chronic kidney disease. Nephron Clin Pract 113(2):c68\u2013c74","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"5140_CR19","first-page":"1533","volume":"72","author":"LA Stevens","year":"2007","unstructured":"Stevens LA et al (2007) Prevalence of chronic kidney disease and the results of the National Kidney Foundation\u2019s Kidney Early Evaluation Program (KEEP). Kidney Int 72(7):1533\u20131539","journal-title":"Kidney Int"},{"issue":"6","key":"5140_CR20","first-page":"1238","volume":"31","author":"STOP-ACEi Study Group","year":"2020","unstructured":"STOP-ACEi Study Group (2020) The impact of stopping angiotensin-converting enzyme inhibitors on progression of chronic kidney disease. J Am Soc Nephrol 31(6):1238\u20131247","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"5140_CR21","first-page":"2385","volume":"31","author":"LA Tomlinson","year":"2020","unstructured":"Tomlinson LA et al (2020) VA NEPHRON-D: randomized trial of dual blockade of the renin-angiotensin system in chronic kidney disease. J Am Soc Nephrol 31(10):2385\u20132397","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5140_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrneph.2015.201","volume":"12","author":"RD Toto","year":"2016","unstructured":"Toto RD (2016) Transplantation: the role of RAAS blockade in kidney transplantation. Nat Rev Nephrol 12(3):129\u201331. https:\/\/doi.org\/10.1038\/nrneph.2015.201","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"5140_CR23","first-page":"3403","volume":"16","author":"MR Weir","year":"2005","unstructured":"Weir MR (2005) Evaluation of losartan in the elderly: a randomized controlled trial. J Am Soc Nephrol 16(12):3403\u20133410","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"5140_CR24","first-page":"1034","volume":"79","author":"MR Weir","year":"2011","unstructured":"Weir MR (2011) The renin-angiotensin-aldosterone system in chronic kidney disease. Kidney Int 79(9):1034\u20131041","journal-title":"Kidney Int"},{"key":"5140_CR25","doi-asserted-by":"publisher","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","volume":"12","author":"MR Weir","year":"1999","unstructured":"Weir MR, Dzau VJ (1999) The renin\u2013angiotensin\u2013aldosterone system: a specific target for hypertension management. Am J Hypertens 12:205S-213S","journal-title":"Am J Hypertens"},{"issue":"9641","key":"5140_CR26","first-page":"717","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S et al (2008) ONTARGET: a randomized trial of telmisartan, ramipril, or both in patients at high risk for vascular events. Lancet 372(9641):717\u2013725","journal-title":"Lancet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05140-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05140-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:20:39Z","timestamp":1781511639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05140-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5140"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05140-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which they belong.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}